Stock · AZN.L · Healthcare
United Kingdom · Large Cap · listed since 1993 · Revenue 12 mo. $61.3B
Price as of 11/06/2026
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.
Original text from the data provider
Summary
56.3 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €7.7B (2025), it supports €86.1B. The remaining €174.6B of the market value assume it grows 15.5% a year for 10 years and not at all afterwards.
Required FCF growth per year
15.5%
no growth afterwards
Price to operating cash flow 21.1×, within its usual range.
Middle half of 20 quarters: 19.9× to 22.1×, median 21.3×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
6 more unchanged: Revenue, 12 mo., Gross margin, EBIT margin, Net debt, Shares outstanding, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 21.01% | 11.52% | Rank 79 |
| Return on capital (Greenblatt) | 93.47% | 32.55% | Rank 90 |
| EBIT margin | 23.40% | 18.31% | Rank 70 |
| FCF margin | 14.76% | 14.12% | Rank 53 |
| Gross margin | 81.90% | 60.99% | Rank 88 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 10.95% | 8.04% | Rank 66 |
| Earnings growth, 3 years per year | 46.01% | 5.44% | Rank 91 |
| Earnings growth, 5 years per year | 20.45% | 7.00% | Rank 84 |
| Sustainable growth (ROE × retained earnings) | 10.05% | 3.66% | Rank 93 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 3.50% | 2.90% | Rank 60 |
| FCF yield | 2.97% | 3.63% | Rank 37 |
| EV/saleslower is better | 5.37 | 4.03 | Rank 38 |
| EV/EBITlower is better | 22.97 | 21.73 | Rank 46 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | −1.07% | 8.66% | Rank 39 |
| Share price, 6 months | 4.75% | 24.27% | Rank 22 |
| Share price, 3 months | 22.23% | 15.42% | Rank 73 |
| Distance from 52-week high | −10.37% | −7.35% | Rank 39 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 2.25% | 0.30% | Rank 34 |
| Change in share countlower is better | −0.06% | 0.00% | Rank 52 |
| Dividend streak in years | 1 | 10 | Rank 29 |
| Price reaction to results, market-adjusted | −0.48% | 0.05% | Rank 41 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 42.66% | 48.40% | Rank 38 |
| Net debt/EBITDAlower is better | 1.20 | 1.11 | Rank 47 |
| Debt to equitylower is better | 0.61 | 0.48 | Rank 43 |
| Volatility, 1 yearlower is better | 27.63% | 31.42% | Rank 75 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2016 | 20.9 | 15.5% | $1.8B | 1.27B | 11.9 |
| 2017 | 23.5 | 15.5% | $2.0B | 1.27B | 14.5 |
| 2018 | 21.0 | 8.3% | $1.2B | 1.27B | 14.4 |
| 2019 | 24.5 | 11.5% | $509.0M | 1.30B | 12.9 |
| 2020 | 29.3 | 17.0% | $2.2B | 1.31B | 12.5 |
| 2021 | 37.1 | 7.6% | $3.8B | 1.43B | 24.4 |
| 2022 | 44.3 | 11.4% | $7.2B | 1.56B | 23.0 |
| 2023 | 46.6 | 20.5% | $6.6B | 1.56B | 22.6 |
| 2024 | 52.9 | 23.7% | $7.3B | 1.56B | 24.6 |
| 2025 | 58.7 | 23.4% | $8.7B | 1.56B | 23.9 |
Score, radar and strategy match for AstraZeneca PLC are visible with Plus. Metrics, price and sector comparison stay free.
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
The match with the 18 strategies checked is visible with Plus.
Selected fundamental metrics for AstraZeneca PLC.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 28.5 | 30.0 |
| P/B ratio | 6.0 | 4.8 |
| Return on equity (ROE) | 21.0% | 11.5% |
| Equity ratio | 42.7% | 48.4% |
| Debt-to-equity (D/E) | 0.61 | 0.48 |
| Dividend yield | 1.7% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| AZN.L | AstraZeneca PLCthis page | |
| GSK.L | GSK plc | locked |
| NOVN.SW | Novartis AG | locked |
| AMGN | Amgen Inc | locked |
| MRK | Merck & Company Inc | locked |
| GILD | Gilead Sciences Inc | locked |
30 days free with all indices, then with Plus.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.